Relapsed/Refractory Archives

November 14, 2023

Epcoritamab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Epcoritamab, a novel subcutaneous (an under-the-skin injection) CD3xCD20 bispecific antibody, resulted in a 62% response rate in high-risk, difficult-to-treat relapsed or refractory (R/R) CLL patients that so far appears to be durable.

October 31, 2023

A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL).

October 18, 2023

Liso-cel, CAR-T Therapy for Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) – ICML 2023

This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.

August 16, 2023

Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy

More research is presented again, proving that targeted therapies, in this case, ibrutinib, are significantly superior to chemoimmunotherapy (CIT) in front-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL).

August 16, 2023

A Study of Frontline Therapy in Adults 80 Years and Older with Chronic Lymphocytic Leukemia (CLL)

In those over 80 with chronic lymphocytic leukemia (CLL), older age and not being treated with a novel agent frontline were associated with increased mortality. The leading cause of death in this group was the CLL itself.

August 16, 2023

Final 7-Year Follow-Up Substudy of Using Venetoclax Combined with Rituximab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

In this final long-term analysis of the groundbreaking MURANO trial, progression-free survival (PFS) and overall survival (OS) benefits for venetoclax-rituximab (VenR) over bendamustine-rituximab (BR) were once again confirmed.

July 14, 2023

ASH 2022: Dr. Meghan Thompson on Treatment Options for CLL After Non-Covalent BTK Inhibitors

Following discontinuation of a non-covalent Bruton tyrosine kinase inhibitor (BTKi), venetoclax is clinically active in patients with CLL or Richter transformation who have not received it in the past. CAR-T therapy may also be an option, but this requires further study.

July 14, 2023

Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent BTK Inhibitor

A newly published paper in the New England Journal of Medicine found that pirtobrutinib shows efficacy in patients with heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had received a covalent Bruton tyrosine kinase inhibitor (BTKi).

May 31, 2023

ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials

This is the largest meta-analysis of AEs reported with covalent BTKIs. The results help us better understand the side effects of BTKIs in CLL

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Relapsed/Refractory

Epcoritamab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Liso-cel, CAR-T Therapy for Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) – ICML 2023

Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy

A Study of Frontline Therapy in Adults 80 Years and Older with Chronic Lymphocytic Leukemia (CLL)

Final 7-Year Follow-Up Substudy of Using Venetoclax Combined with Rituximab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

ASH 2022: Dr. Meghan Thompson on Treatment Options for CLL After Non-Covalent BTK Inhibitors

Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent BTK Inhibitor

ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT